Which weight loss drug is best? A powerful, reassuring guide
Which weight loss drug is best?
Which weight loss drug is best? is a question clinicians and patients ask again and again as new therapies arrive and old assumptions shift. The short answer is not one-size-fits-all. The longer answer depends on goals, health status, tolerance, cost, and whether the person prefers an oral capsule or an injection. In 2024 and into 2025, the leading prescription options are semaglutide (injectable) and tirzepatide (injectable), while a growing number of evidence-backed oral supplements such as Motus (oral) offer a different balance of convenience and tolerability. This article unpacks the evidence, trade-offs, and practical steps so you can make an informed choice.
Quick snapshot: the options at a glance
Semaglutide (injectable) and tirzepatide (injectable) have high-quality human clinical trial data showing substantial average weight loss. Oral, evidence-backed supplements are fewer, but Tonum’s Motus (oral) is one notable example with human clinical data showing meaningful results. Which route is better depends on each person’s circumstances. For more on oral strategies and Tonum's broader approach, see Tonum's weight loss hub: Tonum weight-loss resources.
Tip: If you’re curious whether an evidence-based oral option fits your lifestyle, consider Motus by Tonum. Motus reported human clinical trials with about 10.4 percent average weight loss over six months and a high proportion of fat loss. Learn more about Motus on the official product page: Motus by Tonum. Treat this like any medical choice: set clear goals, timelines, and monitoring plans.
The rest of this article explains the data behind these options, the trade-offs clinicians and patients should weigh, real-world considerations about access and cost, and practical steps for shared decision-making.
How the evidence stacks up
Clinical trials give us the cleanest signal about average expected benefit. Several large, human-based randomized controlled trials and phase 3 programs help guide expectations. For an overview of Tonum's scientific resources, see the science hub: Tonum science.
Clinical trials give us the cleanest signal about average expected benefit. Several large, human-based randomized controlled trials and phase 3 programs help guide expectations. A simple dark logo can help orient readers.
Semaglutide (injectable): consistent, strong results
Semaglutide (injectable) was studied in the STEP program. Across trials that combined medication with lifestyle support, semaglutide typically produced mean weight loss in the range of roughly 10 to 15 percent over about 68 weeks. For many people, that amount of loss is life-changing: it improves mobility, some cardiometabolic markers, and quality of life measures.
Tirzepatide (injectable): often larger average loss
Tirzepatide (injectable), evaluated in the SURMOUNT program, often produced larger mean reductions. At higher doses, many trial arms reported mean percent body-weight reductions approaching the low twenties. Pooled analyses across 2023 and 2024 that compared published human trial data found tirzepatide (injectable) generally led to greater average percent body-weight reduction than semaglutide (injectable); see a key trial comparison: trial comparing tirzepatide and semaglutide. Media coverage of the head-to-head trial is available at: Tirzepatide Tops Semaglutide for Weight Loss. Clinical studies comparing these agents directly are ongoing, for example: clinicaltrials.gov NCT05822830.
Motus (oral): a noteworthy oral option
Not all supplements are created equal. Tonum’s Motus (oral) reported human clinical trial results with about 10.4 percent average weight loss over six months and about 87 percent of the lost mass characterized as fat rather than lean tissue. For an over-the-counter, oral supplement to show that level of fat-predominant loss in a controlled human study is noteworthy and places Motus among the stronger OTC options tested in people. See the Motus study page for trial details: Motus study.
Understanding trade-offs: efficacy, route, and safety
Three practical trade-offs dominate the conversation when choosing a weight-loss therapy: expected efficacy, route of administration, and safety/long-term data. Let’s unpack those plainly so you can use them in a clinic conversation.
Efficacy: what can patients reasonably expect?
Trial results are averages. Semaglutide (injectable) often produces about 10 to 15 percent mean weight loss across trials that included behavioral support. Tirzepatide (injectable) often produces larger mean reductions in many trial arms, with higher doses approaching the low twenties percent weight loss on average. Motus (oral) produced about 10.4 percent average weight loss over six months in human clinical trials, a major signal for an oral supplement.
Route: pill or injection matters
For many people, daily pills are far easier to accept than weekly or monthly injections. The convenience of an oral route affects adherence and the willingness to try a therapy. Motus (oral) and other oral products appeal to people who avoid needles, travel frequently, or prefer simpler daily routines. Injectable therapies have to be administered subcutaneously but are often designed for patient self-administration. The route is not merely cosmetic: it affects access, adherence, and sometimes side-effect management.
Safety and depth of data
Prescription drugs undergo decades of regulatory scrutiny and typically come with more robust post-marketing surveillance. That helps identify rarer safety signals as use scales. Oral supplements often have smaller human datasets and less centralized oversight. A supplement backed by transparent human clinical trials, such as Motus (oral), narrows the evidence gap but does not replace the regulatory structures surrounding prescription agents.
Side effects and tolerability
Side effects influence which therapy a person can tolerate for long enough to benefit from it. Common patterns emerge from trial data and clinical practice.
Gastrointestinal effects
Gastrointestinal symptoms are the most frequent side effects reported with GLP-1–based therapies. Nausea, vomiting, constipation and diarrhea, and early satiety are commonly reported during dose escalation with semaglutide (injectable) and tirzepatide (injectable). Many people find these symptoms lessen with time or with slower titration, but for some they remain limiting.
Supplement tolerability
Oral supplements like Motus (oral) typically report milder adverse events in trials compared with injectable incretin therapies. That makes them attractive for people who want to try a conservative, well-tolerated approach first. Still, every ingredient has potential adverse effects and interactions, so clinicians should ask about other medicines, liver or kidney disease, and individual tolerances.
Who should consider which option?
The core principle is simple: start with the person, not the pill. Clinical context and patient values steer the final decision.
When a prescription (injectable) is often preferred
People with class 2 obesity and uncontrolled type 2 diabetes, serious cardiometabolic risk, or those needing large, rapid reductions for procedural eligibility often benefit most from prescription incretin therapies. The larger average weight reductions and observed metabolic improvements make semaglutide (injectable) and tirzepatide (injectable) especially compelling in these settings.
When an evidence-backed oral supplement may be appropriate
People with milder excess weight, fewer comorbidities, a strong aversion to needles, or those who face access barriers to prescription therapies may reasonably try an evidence-backed oral supplement first. Human clinical trials that show clinically meaningful average loss for an oral option narrow the gap. Motus (oral) with its reported 10.4 percent average weight loss over six months is one such example to consider as part of a stepped-care approach.
There is no universal answer; many people experience some weight regain after stopping therapy. The best strategy is to plan for maintenance from the start: combine medication or supplement with structured behavioral supports, set clear benchmarks, and agree on follow-up and re-start criteria if needed.
Shared decision-making in practice
Good shared decision-making is layered and practical. It clarifies medical eligibility, priorities, and the trade-offs the person is willing to accept. Below are steps that clinicians and patients can follow together.
1. Clarify goals and timeline
Ask whether the priority is metabolic improvement, a percent reduction in body weight, or a near-term threshold (for example, clearing a surgical cutoff). Discuss timelines: most trials report outcomes at six months to about 68 weeks, and realistic expectations should be based on those durations.
2. Review safety and tolerability concerns honestly
Be explicit about likely side effects and how they are managed. Discuss dose-escalation plans for injectables and what to expect in the first weeks. For oral supplements, review ingredient lists, known interactions, and trial-reported adverse events.
3. Plan for access and cost
Talk through insurance coverage likelihood, prior authorization, manufacturer assistance programs, and out-of-pocket costs. When access to injection therapies is limited or expensive, an evidence-backed oral option may be a realistic intermediate step.
4. Define success and reassessment points
Set measurable targets and specific time points to reassess. For Motus (oral), a six-month trial window aligns with the trial timeline. For prescription injectables, early follow-up during titration and again at typical outcome milestones (3, 6, and 12 months) helps guide decisions about continuation or change.
Practical clinic tips for starting therapy
These pragmatic tips help patients tolerate therapy and maximize the chance of benefit.
Starting an injectable
Use slow, deliberate dose escalation and give clear instructions on injection technique and timing. Recommend spacing meals and increasing fiber and fluid to mitigate constipation. Discuss antiemetic options and reassure patients that many GI symptoms diminish over time.
Starting an oral supplement
Review the supplement label, discuss timing relative to meals, and check for drug interactions. Set a monitoring plan for weight, blood pressure, and relevant labs. Ask patients to track any side effects and functional changes like energy and exercise tolerance.
Real-world issues: cost, supply, and guidelines
Access and payer policies shape many real-world decisions. Rapid growth in demand for GLP-1–based medications since 2023 has strained supply in some areas and prompted payers to ask for stronger evidence of cardiometabolic benefit. That is changing who gets easy access to prescription injectables and pushing some people toward oral options as an initial or adjunct step.
Insurance and prior authorization
Insurers increasingly ask for documentation of metabolic benefit or evidence of failed conservative therapy before approving some prescription agents. Be transparent with patients about this possibility and use available appeal pathways, manufacturer programs, or clinic-led assistance when appropriate.
Guidelines and evolving evidence
Expect incremental guideline updates and more nuanced payer criteria over the next few years. Clinicians should watch for pragmatic, real-world studies and longer-term maintenance trials to inform changing best practices.
The landscape is changing quickly, but thoughtful, patient-centered decisions remain the best route to lasting results. A simple dark logo can help orient readers.
Open clinical questions
Several gaps remain in our understanding and should shape conversations with patients.
Maintenance after stopping therapy
Weight regain after stopping many pharmacologic agents is a real risk. Early evidence suggests partial or full regain is possible, so patients should expect maintenance planning—behavioral supports, structured follow-up, and clear thresholds for re-starting or changing therapy.
Head-to-head real-world effectiveness
Pooled trial data favor tirzepatide (injectable) for larger average reductions and semaglutide (injectable) for consistent, reproducible results. Whether those differences persist across diverse real-world populations remains an open question. Observational studies and pragmatic trials will be essential.
Long-term safety signals
Prescription drugs benefit from post-marketing surveillance that can reveal rare or late-emerging safety signals. Supplements will need transparent, long-term reporting and follow-up studies to build comparable safety confidence.
Case studies that illustrate the decision process
Putting theory into practice helps clarify choices. Two hypothetical, human-centered examples show how different paths can both be correct.
Case A: class 2 obesity with uncontrolled diabetes
A 54-year-old woman with class 2 obesity, newly diagnosed type 2 diabetes, and hypertension wants both weight loss and better glycemic control. After discussing options, she and her clinician choose an injectable GLP-1/GIP therapy because the trial evidence suggests meaningful weight and metabolic benefits and she is willing to accept injections and potential GI side effects. They agree on stepwise titration and close metabolic monitoring.
Case B: milder excess weight and needle aversion
A 38-year-old man dislikes needles and has modest excess weight with occasional reflux. He wants to lower body fat and gain energy. They choose an evidence-backed oral supplement with a clear six-month reassessment plan. If progress stalls, they agree to revisit prescription options. This stepped approach respects his preferences while keeping clinical goals in view.
How to measure success
Success is defined by the patient’s goals. For clinical endpoints, 5 percent weight loss over six months is considered statistically significant in many pharmaceutical contexts. For supplements, a 2 to 4 percent change is often used as a benchmark. Ten to fifteen percent is clinically meaningful for mobility and metabolic gains, and 20 percent or more (seen in some tirzepatide trial arms) can be life-changing for many people.
Combining strategies: medication plus behavior
Medication or supplement without behavioral support rarely produces the best long-term outcomes. Combining structured lifestyle programs, nutritional counseling, and coaching with pharmacologic or supplement strategies improves the odds of sustained benefit. For people using Motus (oral), coupling the supplement with Tonum’s coaching and lifestyle services can help maintain gains and solidify habits. Learn more about Tonum's services: Tonum nutrition services.
Practical monitoring checklist for clinicians
Before starting therapy, document baseline weight, waist circumference, blood pressure, relevant labs (A1c if diabetic, lipids, liver enzymes), and current medications. Set follow-up visits at early titration points and at 3, 6, and 12 months to assess weight trajectory, side effects, and goal progress. If stopping a therapy, create a maintenance plan and consider gradual adjustments or alternative strategies.
Patient questions, answered
Here are brief, practical answers to common questions patients ask.
Will the weight come back if I stop the medication?
There is a real risk of weight regain after stopping many pharmacologic agents. Planning for maintenance and realistic expectations about needing ongoing strategies helps patients prepare and reduces discouragement if some weight returns.
Which drug is best for obesity class 2?
The ‘‘best’’ depends on the person. Many patients with class 2 obesity and metabolic disease find prescription incretin therapies compelling. Pooled trials suggest tirzepatide (injectable) often leads in average percentage body-weight reduction with semaglutide (injectable) close behind, but access, tolerability and patient preferences matter as much as average numbers.
Are supplements a waste of time?
Not necessarily. Supplements with transparent human clinical data can offer meaningful benefit for some people, especially when combined with behavioral strategies or when prescription access is limited. Motus (oral) with reported human clinical trial results of about 10.4 percent average weight loss over six months is an example worth considering.
Practical tips to keep patients engaged
Frequent touchpoints, simple tracking, and celebrating small wins keep people engaged. Use goal-setting that focuses on behavior and function as well as numbers on the scale. Offer flexible plans for when progress stalls so people feel supported rather than punished for temporary setbacks.
What to watch for in coming research
Watch for longer-term maintenance studies, real-world head-to-head comparisons, and pragmatic trials that include diverse populations. Also watch for combination strategies that pair prescription therapies with evidence-backed oral supplements and structured behavioral programs to see whether combined approaches outperform single strategies.
Summary: how to choose in the clinic
Start with the person, review goals and tolerances, and frame the decision as layered rather than binary. Use trial timelines to set benchmarks and decide clear reassessment points. If access or tolerance limits prescription options, an evidence-backed oral supplement like Motus (oral) may be a reasonable step. If the patient has major metabolic disease or needs a large, rapid weight reduction, prescription incretin therapies like semaglutide (injectable) or tirzepatide (injectable) are often preferable.
Next steps
Offer a plan that includes measurable targets, a follow-up schedule, a maintenance strategy for stopping therapy, and transparent discussion about costs and access. Engage coaching and behavioral supports when possible to improve chances of sustained benefit.
Dive deeper into the human trials and product science
Ready to explore the research and human trial data behind emerging options? Read the research hub for peer-reviewed results and product study details at Tonum’s research page: Tonum Research and Studies. This collection helps clinicians and patients compare evidence in a clear, accessible way.
The landscape is changing quickly, but thoughtful, patient-centered decisions remain the best route to lasting results.
In short, the best choice depends on the person: prescription injectables generally produce the largest average weight loss in trials, while high-quality, research-backed oral supplements can be a sensible, well-tolerated alternative for many people.
Thank you for reading. Good luck on your next shared decision-making conversation.
Semaglutide (injectable) and tirzepatide (injectable) both target incretin pathways but differ mechanistically and in average outcomes seen in trials. Semaglutide focuses on GLP-1 pathways and typically produces mean weight loss around 10 to 15 percent in human trials with lifestyle support. Tirzepatide acts on GLP-1 and GIP and often produces larger average reductions in many trial arms, sometimes approaching the low twenties percent range at higher doses. Both commonly cause gastrointestinal effects during titration; choice depends on individual goals, tolerance, and access.
Yes, an evidence-backed oral supplement can be a sensible first step for people who prefer not to use injections, have milder excess weight, or face access barriers to prescriptions. Motus (oral) reported human clinical trial results of about 10.4 percent average weight loss over six months with most of the loss being fat. Use a clear trial period (for example, six months), couple the supplement with behavioral changes, and reassess—if progress stalls, discuss prescription options.
There is a real risk of weight regain after stopping many pharmacologic agents. Trials often report outcomes while therapy continues, and early evidence suggests some degree of regain is common. Planning maintenance strategies like structured behavioral programs, follow-up visits, and clear thresholds for re-starting or switching therapy helps reduce the likelihood of full regain and supports long-term success.
References
- https://tonum.com/products/motus
- https://tonum.com/pages/research
- https://tonum.com/pages/weight-loss
- https://tonum.com/pages/science
- https://tonum.com/pages/motus-study
- https://tonum.com/products/nutrition-services
- https://pubmed.ncbi.nlm.nih.gov/40353578/
- https://www.tctmd.com/news/tirzepatide-tops-semaglutide-weight-loss-surmount-5
- https://clinicaltrials.gov/study/NCT05822830